Overview of Daktarin

Quick Facts

Property	Description
Active ingredient	Miconazole nitrate
Pharmacological class	Azole Antifungal Agent (Imidazole)
Origin	Synthetic compound
Common forms	Cream, powder, oral gel, pessaries
General purpose	Combatting fungal and yeast infections (mycoses)

Daktarin: An Azole Antifungal and Synthetic Compound

Daktarin is a medicinal entity defined by its active ingredient, Miconazole nitrate, which is a synthetic compound developed for therapeutic use against mycoses. It is formally classified as an azole antifungal agent, belonging to the imidazole derivative group, a classification based on its mechanism against fungal pathogens. Miconazole is utilized for infections of the skin, nails, and mucous membranes, establishing it as an option in topical antimycotic therapy. Unlike some azoles, Miconazole also exhibits a recognized secondary action against certain Gram-positive bacteria, a differentiating factor that contributes to its utility in managing mixed-type surface infections.

The Available Forms: Topical and Mucosal Preparations

Miconazole nitrate is incorporated into various pharmaceutical preparations to ensure targeted delivery where the fungal organism is active. Common dosage forms include a cream and powder for external skin applications, an oral gel designed for mucosal infections in the mouth, and pessaries for localized internal treatment. This variety defines the route of administration as primarily topical or mucosal. Each formulation uses a specific base/vehicle appropriate for the application site; for instance, the oral gel utilizes an adhesive vehicle, which is a key differentiating factor allowing the drug to remain in contact with the buccal mucosa for sustained action.

General Purpose: Combatting Fungal Infections

The core function of Miconazole nitrate is its broad-spectrum antimycotic activity, dedicated to eliminating the pathogens responsible for fungal infections. This is achieved through a dual effect: the primary mechanism results in a fungistatic action, which halts the proliferation of the fungi, and a fungicidal effect, which acts to destroy the fungal organism. This dual action allows the medicine to address a wide range of surface mycoses, making it an established agent in both over-the-counter and prescription contexts depending on the concentration and dosage form.

Regulatory References

MedlinePlus

What side effects are possible with Daktarin?

Possible Side Effects and Safety Information (Miconazole Topical)

The safety profile for topical miconazole (Daktarin) is based on official government regulatory documents and highlights local reactions as the most common adverse events.

Documented Adverse Reactions

The most frequent side effects reported involve the application site, with reactions classified by regulatory agencies based on frequency:

Frequency	Side Effect Examples
Uncommon (Affects 1 in 1,000 to 1 in 100 people)	Skin burning sensation, Application site irritation, Application site burning, Application site pruritus (itching), Skin inflammation, Skin hypopigmentation.
Not Known (Cannot be estimated from available data)	Hypersensitivity, Urticaria (hives), Contact dermatitis, Rash, Erythema, Pruritus, Angioedema.

Serious Safety Considerations

While rare due to minimal systemic absorption, the safety profile documents the potential for serious adverse reactions:

Serious Allergic Reactions: Anaphylactic reaction and Angioedema have been reported in post-marketing experience (frequency Not Known). If signs of a severe allergic reaction or significant irritation occur, the product must be discontinued immediately.

Population-Specific Cautions and Limitations

Official labeling includes specific safety warnings and restrictions:

Contraindication: Daktarin is contraindicated for individuals with a known hypersensitivity or allergy to miconazole, other imidazole derivatives, or any of its excipients.
Pregnancy and Lactation: Use during pregnancy and breastfeeding should be done with caution. Although systemic absorption is minimal, it is not known whether miconazole is excreted in human breast milk.
Drug Interaction Warning: Caution is advised if the medicine is used concurrently with oral anticoagulants, such as warfarin. Due to the minimal risk of interaction, the anticoagulant effect should be monitored by a healthcare professional.
Excipient Warnings: The product must not come into contact with the eyes. Specific excipients, like Benzoic acid, require caution when used in newborn babies (up to 4 weeks old) due to the potential to increase jaundice.

Overdose and Emergency Response

Daktarin Overdose and When to Seek Help

Overdose with topical formulations of Daktarin (miconazole) is highly unlikely due to minimal systemic absorption when applied to the skin. Excessive use may result primarily in local reactions, such as increased skin irritation, redness, or a burning sensation at the application site. If this occurs, it is generally recommended to temporarily stop the application and then resume treatment at the prescribed dose or seek advice from a healthcare professional if symptoms persist.

Accidental ingestion of large quantities of the cream or gel formulation may lead to gastrointestinal distress. Symptoms reported following accidental ingestion, particularly of the oral gel, may include nausea, vomiting, and diarrhea. If a significant amount of the product is swallowed, contact your local poison control center or emergency room immediately for guidance.

Immediately seek emergency medical attention (call 911 or your local emergency number) if you experience signs of a severe allergic reaction (anaphylaxis), which, while rare, requires urgent treatment. These signs include:

Symptom Category	Signs of Severe Allergic Reaction (Anaphylaxis)
Respiratory	Difficulty breathing, wheezing, or tightness in the chest or throat
General	Swelling of the face, lips, tongue, or throat; severe rash, hives, or itching
Circulatory	Severe dizziness or fainting

Therapeutic Uses of Daktarin

What Daktarin Treats: Main Uses and Benefits

The medication is commonly used to help manage specific infections, such as those caused by dermatophytes (including the fungi responsible for Ringworm, Athlete’s foot, and Jock itch) and Pityriasis versicolor. The medication is also applied to address superinfections due to Gram-positive bacteria. This comprehensive approach helps manage symptom patterns that include itching, burning, scaling, and cracking of the skin, generally providing supportive relief that assists patients in coping more steadily with these distressing manifestations.

The medicine is commonly used for managing conditions driven by Candida yeast, and is relevant for conditions such as oral thrush, cutaneous candidiasis in skin folds, and vulvovaginal candidiasis. It is used to help address the associated symptoms of soreness, redness, and the presence of white or discolored patches on the linings of the mouth or in sensitive areas. This agent is relevant in clinical settings marked by periods of heightened symptoms, particularly when the itching and localized burning sensation become more noticeable.

Quick Fact: Supportive Relief for Fungal Discomfort
Symptom Focus	Itching, burning, scaling, and soreness from fungal and yeast infections.
Key Benefit	Supports the patient during difficult episodes by easing the overall symptom load and assisting with maintaining functional stability.
Use Context	Applied in scenarios involving acute or recurrent surface mycoses and symptoms that interfere with daily functioning.

Eligibility and Restrictions for Use

Daktarin (miconazole) is an antifungal medication available in different formulations, such as topical creams and oral gels. The suitability of the product depends heavily on the specific formulation and the patient's medical history.

Who Can Use Daktarin?

Adults and Children: Topical creams are generally suitable for adults and children of all ages for skin infections like athlete's foot and ringworm. Daktarin Oral Gel is approved for use in adults and children from 4 to 6 months of age and older, depending on the region and the development of the child's swallowing reflex.
Infections: It is used for skin and nail infections caused by fungi, yeasts, and associated Gram-positive bacteria.

Who Cannot Use Daktarin? (Contraindications)

All formulations are contraindicated for individuals with known hypersensitivity or allergy to miconazole, other imidazole antifungal derivatives (like ketoconazole), or any of the product's inactive ingredients. Specific contraindications for the Oral Gel include:

Infants under 4-6 months of age, or those with an insufficiently developed swallowing reflex, due to the risk of choking.
Patients with liver dysfunction.
Patients taking certain medications metabolized by the CYP3A4/2C9 enzyme system, such as some oral anticoagulants (e.g., warfarin), specific cholesterol-lowering drugs (e.g., simvastatin), and certain anti-anxiety or sleep medications (e.g., triazolam). Close medical supervision and dosage adjustment are required when using miconazole with many other medications.

Use During Pregnancy and Breastfeeding

Pregnant or breastfeeding individuals should consult a healthcare professional before use. While systemic absorption is generally limited with topical application, the risks versus benefits should be assessed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information confirms that Daktarin (Miconazole) can alter the effects of certain co-administered medicines, primarily due to the active ingredient's role as an inhibitor of the CYP3A4 and CYP2C9 enzyme systems. This metabolic inhibition leads to increased plasma concentrations (exposure) of many drugs cleared by these pathways.

Contraindicated Combinations

Co-administration of the oral gel is formally prohibited by regulatory authorities with several drug classes due to the risk of severe reactions, including the potentiation of effects. Prohibited combinations include, but are not limited to:

QT-Prolonging Agents (e.g., Astemizole, Cisapride, Mizolastine, Terfenadine)
Ergot Alkaloids (e.g., Ergotamine, Dihydroergotamine)
Certain Statins (Simvastatin, Lovastatin)
Oral Benzodiazepines (Triazolam, Oral Midazolam)

Exposure-Altering and Potentiating Effects

Miconazole may enhance the therapeutic effect of other drugs, necessitating monitoring and possible dosage adjustment. The regulatory label explicitly details interactions with:

Oral Anticoagulants (Warfarin): Enhances the anticoagulant effect, which can increase the risk of bleeding. Over-the-counter Miconazole Oral Gel is contraindicated in patients taking Warfarin in some regions.
Oral Hypoglycaemics (Sulfonylureas): Potentiation of the glucose-lowering effect, which may lead to hypoglycaemia.
Immunosuppressants (Cyclosporine, Tacrolimus): Increases plasma levels, requiring close monitoring.
Phenytoin: Slows the metabolism of Phenytoin, requiring plasma level monitoring.

Finally, the use of oral Miconazole is formally contraindicated in patients with liver dysfunction, as impaired liver function could further exacerbate the risk of drug accumulation and interaction severity.

Mechanism of Action

How Daktarin Works: Mechanism of Action

Miconazole targets the fungal cell by inhibiting the enzyme Cytochrome P450 14alpha-lanosterol demethylase (CYP51). This blockage prevents the biosynthesis of ergosterol, the key structural sterol of the fungal cell membrane, leading to the accumulation of toxic intermediate sterols. The resulting functional and structural impairment of the membrane initiates the fungistatic effect by preventing cellular proliferation.

Beyond blocking synthesis, Miconazole also directly disrupts membrane phospholipids and inhibits the fungal cell’s antioxidant enzymes (catalase and peroxidase). This dual action results in the rapid buildup of damaging Reactive Oxygen Species (ROS), causing severe oxidative stress and cellular necrosis. This provides the concentration-dependent fungicidal effect, which results in the active destruction of the fungal cell.

The drug further interferes with the fungus's ability to switch between its unicellular yeast form and its filamentous mycelial form (hyphae). This inhibition of morphological transition functionally confines the pathogen to the unicellular form.

Dosage and Administration Information

How to Use Daktarin: Administration Guidelines

The usage of Miconazole nitrate (Daktarin) is determined by the pharmaceutical form, utilizing either a topical (cutaneous) or local oral mucosal route.

Topical Administration: The cream or powder is typically applied twice daily as a thin layer to the affected skin and surrounding area. For Tinea versicolour, application may be reduced to once daily. To complete the course, treatment often continues for 10 to 14 days after the visible lesions have disappeared. The cream should be rubbed in thoroughly until absorbed. For infections of the feet, powder is often dusted inside articles of clothing or shoes that are in contact with the infected area. The dosage frequency is the same for adults and children of all ages.

Oral Gel Administration: The oral gel is administered into the mouth for local action, usually at a dose of 2.5 mL (half a measuring spoon) four times daily. The gel is applied after meals to help the active substance remain in contact with the oral mucosa for a sustained period before swallowing. Treatment for oral candidosis must continue for at least one week after symptoms have disappeared.

Age-Specific Administration: Infants between 4 and 24 months receive a reduced dose of 1.25 mL four times daily. The infant dose is administered in divided, small portions applied to the front of the mouth with a clean finger to ensure proper handling.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Daktarin (Miconazole)

Evidence for Vulvovaginal Candidiasis (VVC) Studies

Research has examined miconazole for conditions characterized by fluctuating or episodic manifestations, specifically vulvovaginal candidiasis (VVC). Studies explored the use of formulations designed for vaginal use in randomized controlled trials (RCTs), often comparing them against inactive formulas (placebo) or other similar antifungal medicines. The key outcomes that were monitored in these trials included therapeutic cure (which meant documenting how symptoms evolved, such as physical discomfort and irritation) and reaching the endpoint of mycological cure through laboratory tests.

The findings describe patterns observed where the medicine was included in research exploring how symptoms change over defined time intervals. Some trials described patterns consistent with pre-defined therapeutic cure endpoints when assessed against a placebo. Studies reported that most participants documented changes in outcomes related to physical discomfort within about seven days.

Evidence for Oropharyngeal Candidiasis (Oral Thrush) Studies

Research has explored the use of miconazole in forms designed for the mouth, such as gels and mucoadhesive tablets, to treat Oropharyngeal Candidiasis (Oral Thrush). These trials primarily included adults and monitored outcomes related to systemic or functional imbalance, such as changes in physical signs and laboratory confirmation of yeast eradication. Studies focusing on episodes where symptoms become more noticeable were often conducted in specific groups, including patients with diabetes and individuals living with HIV infection.

Findings indicate patterns related to the medicine’s use, often reporting its performance against other common oral treatments like nystatin or fluconazole. For high-risk groups like patients with HIV, evidence suggests that the medicine's activity appears to be comparable to other commonly prescribed oral antifungals.

What is Still Uncertain About Daktarin’s Research

The research base has several known gaps, which is common for medicines that have been in use for many decades. Evidence quality varies across studies, with some older trials showing methodological shortcomings that introduce potential bias. Comparative evidence is lacking for certain groups, as the vast majority of studies focus on specific, high-risk populations, limiting the generalizability of the findings to the average person.

Specifically, the follow-up durations were limited in many primary efficacy trials, meaning research provides context but not individual predictions about the durability of effect or the likelihood of an infection returning over a long period. The research concerning onychomycosis reported no significant difference from placebo, leaving the role of topical miconazole for nail fungus is an area where research provides limited insight.

Key Studies & References Antifungal (oral and vaginal) therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Daktarin (FAQ)

Q: What is the main ingredient in Daktarin?

The main, active ingredient in Daktarin is Miconazole nitrate. This is the substance that is responsible for targeting the fungal cells to help resolve the infection.

Q: What is the purpose of the active ingredient, miconazole?

Miconazole nitrate is officially classified as an imidazole antifungal agent. This means its primary purpose is to treat fungal infections, as it has a wide range of activity against various types of fungi. Some official documentation also notes that the medicine is described as possessing some activity against certain Gram-positive bacteria.

Q: What class of drug does Daktarin belong to?

The active ingredient, Miconazole, belongs to the class of medicines known as azoles. It is specifically classified as an imidazole antifungal agent.

Q: Is Daktarin a steroid?

No, Miconazole is classified as an imidazole antifungal agent. It is a different type of medicine and does not belong to the steroid drug class.

Q: Is the active ingredient in Daktarin a new or old medicine?

Miconazole is considered a well-established medicine. The active ingredient was patented in 1968 and approved for medical use in 1971, meaning it has been in use for several decades.

Q: Does Daktarin come as a cream, powder, or tablet?

Official sources describe the availability of the medicine in multiple forms to address infections in different parts of the body. This includes a topical cream, a powder, and an oral gel. In certain regions, a buccal tablet may also be available.

Q: Are there different strengths of Daktarin cream?

The topical cream form of the medicine is most commonly supplied at a concentration of 2% Miconazole nitrate.

Q: Is Daktarin available over the counter?

In many areas of the world, topical forms containing Miconazole, the active ingredient, are generally classified as Over-the-Counter (OTC) drug products. The OTC classification is based on regulatory decisions for treating specific, common fungal skin conditions.

Q: Is Daktarin used for conditions other than athlete's foot?

According to official product information, Daktarin (miconazole) is approved for a range of fungal infections, not just athlete's foot. This includes common conditions like tinea cruris (jock itch) and tinea corporis (ringworm). Other formulations are approved for use in yeast infections such as oral candidiasis (oral thrush) and vulvovaginal candidiasis.

Q: Is Daktarin a treatment for ringworm?

Yes, the topical cream containing Miconazole is officially labeled for the treatment of fungal infections, including ringworm (which is clinically referred to as tinea corporis).

Q: Does Daktarin treat bacterial infections?

Miconazole is primarily classified and used as an antifungal agent. However, official documentation for the topical forms indicates its classification for the treatment of superinfections that are caused by certain Gram-positive bacteria.

Q: Why does Daktarin have different forms (oral vs. topical)?

The different formulations are provided because they are approved for treating infections in specific, different locations on the body. For example, the topical cream or powder is intended for skin infections, while the oral gel is used to treat infections that occur in the mouth.

Q: How does the oral form of Daktarin work differently from the cream?

Both the topical cream and the oral gel contain the same active ingredient, Miconazole, which works by the same mechanism to target fungal cells. The primary difference lies in the administration route and the degree to which the active substance is absorbed. The cream is applied to the skin, while the oral gel is used for local action in the mouth.

Q: What does the term 'broad-spectrum antifungal' mean for Daktarin?

The active ingredient is described in regulatory documents as possessing a wide antifungal spectrum. This classification indicates that the medicine is active against a large range of different fungi. Some official documentation also notes that the medicine is described as possessing some activity against certain Gram-positive bacteria.

Q: What happens if I stop using Daktarin too soon?

Official administration guidelines require that the full course of treatment be completed. The continued use for a defined period, even after the visible signs have disappeared, is intended to help ensure the infection is completely cleared and reduce the chance of the infection returning.

Q: What kind of lesions disappear 10 to 14 days after the visible ones are gone?

The lesions referred to in the administration guidelines are the visible physical signs of the fungal skin infection being treated. The requirement to continue treatment for 10 to 14 days after these visible signs have disappeared is intended to help ensure the infection is fully eradicated from the skin.

Q: What is the typical time frame to see improvement with Daktarin?

The official drug label for the topical cream provides a timeframe for when initial improvement is expected. For conditions like jock itch, the label indicates improvement within two weeks, and for athlete's foot or ringworm, improvement is typically expected within four weeks.

Q: What are the general expectations for treatment with Daktarin?

Official guidelines for topical use often state that improvement is generally expected within two to four weeks, depending on the type of infection. Treatment is intended to be continued for a defined period even after the visible signs of the infection have disappeared to help reduce the risk of the infection returning.

Q: Are the side effects of Daktarin usually mild?

The most frequently reported side effects for the topical cream involve the application site, such as a skin burning sensation or itching, and these are often classified as uncommon. Regulatory documents also describe the potential for serious allergic reactions, with the frequency of these reactions being estimated as not known from available data.

Q: Can Daktarin be used on sensitive skin areas?

The official labeling includes warnings related to specific inactive ingredients (excipients), such as benzoic acid and butylated hydroxyanisole, which have the potential to cause local skin reactions or irritation. There are specific cautions regarding the use of the product in newborn babies.

Q: What is Daktarin's status regarding gluten or common allergens?

Official documents list the inactive ingredients, or excipients, contained in the medicine. Warnings are provided for specific excipients, such as benzoic acid and butylated hydroxyanisole, because of the potential to cause local skin irritation. The label also contains specific cautions regarding the use of the cream in newborn babies due to excipient-related risks.

Q: What if I accidentally swallow a small amount of Daktarin cream?

The official drug label provides safety instructions in case the cream is accidentally swallowed. It instructs that medical help or a Poison Control Center is to be contacted right away for further guidance.

Q: How is Daktarin generally classified for safety?

Miconazole is classified as an imidazole derivative, belonging to the class of antifungal agents. Regulatory bodies in some regions, such as the Therapeutic Goods Administration (TGA) in Australia, categorize the drug as Pregnancy Category A. These safety categories vary by region.

Q: Can I use Daktarin if I have diabetes?

According to regulatory information, people who take certain oral anti-diabetic medicines, like sulfonylureas, should be aware of a possible interaction with the oral form of miconazole. The medicine may enhance the effect of these drugs, which could increase the risk of low blood sugar. This known interaction is noted in regulatory documents.

Q: Is Daktarin approved for use in all countries?

Miconazole is listed in international drug classification systems, suggesting wide global availability and use. However, the specific regulatory status and approved uses of the Daktarin brand and its formulations can vary from one country to another.

How should Daktarin be stored and disposed of?

How to Store and Dispose of Daktarin?

Storage: Keep Daktarin (miconazole) cream or gel in its original packaging in a cool, dry place. The temperature should generally remain below 25 C or 30 C, depending on the specific formulation, and away from direct heat and moisture. Do not store this medicine in a bathroom or near a sink. Always ensure that the product is kept out of the sight and reach of children and pets, ideally in a locked cupboard. Do not use the medicine past the expiration date printed on the packaging.
Disposal: Do not dispose of unused or expired Daktarin by flushing it down a toilet or pouring it down a sink, as this may be harmful to the environment. The recommended method for disposal is to take any leftover medication to a local pharmacy or a community drug take-back program. If a take-back option is unavailable, mix the medicine with an undesirable substance like dirt or used coffee grounds, seal the mixture in a plastic bag, and place it in the household trash.

Daktarin